Coya Therapeutics Inc. (COYA)
NASDAQ: COYAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
COYA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $69.20M
- EPS (TTM)
- -$1.39
- Dividend yield
- None
- 52-week range
- 2.72 – 6.62
- Day range
- 2.90 – 3.11
- Volume / Avg
- 138.27K / 149.18K
- Beta
- —
- Shares outstanding
- 23.46M
52-week range
COYA stock today
Shares of Coya Therapeutics (COYA) finished lower on Nov 20 at $2.95, a drop of 1.01% or $0.03 per share, versus the S&P 500's 3.70% decline. At this level, COYA sits near the bottom of its 52-week range of $2.72 to $6.62: 55.4% below the high, set on Dec 1, 2025 and 8.5% above the low. COYA is down 49.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 50.7%.
Coya Therapeutics has posted a net loss over the last twelve months (EPS of -$1.39), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Coya Therapeutics
Company profileCoya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Arun Swaminathan Ph.D.
- Headquarters
- Houston, TX
- Employees
- 8
- IPO year
- 2022
- Website
- coyatherapeutics.com
Financial highlights
Full financialsIn fiscal 2025, Coya Therapeutics generated $7.9 million in revenue, up 123.6% from fiscal 2024. Coya Therapeutics reported a net loss of $21.2 million, compared with a loss of $14.9 million a year earlier. Operating margin was -283.9%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $7.95M | $3.55M | $6.00M | $0 | — |
| Growth | +123.57% | -40.79% | — | — | — |
| Net income | $-21.23M | $-14.88M | $-7.99M | $-12.24M | $-4.89M |
| EPS (diluted) | $-1.27 | $-0.98 | $-0.79 | $-4.73 | $-1.89 |
Analyst forecast
ForecastConsensus (7 analysts)
strong_buy
Avg. price target
$15.21+415.59%
- Strong buy 0
- Buy 7
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 11, 2026
- EPS actual vs est.
- $-0.45 vs $-0.35
- Surprise
- -28.57%
COYA news
All COYA newsCoya Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ZYBTZhengye Biotechnology Holding Limited Class A | 1.48 | -2.63% | $70.14M | vs COYA |
| MAIAMAIA Biotechnology Inc. | 1.11 | -2.63% | $68.54M | vs COYA |
| CINGCingulate Inc. | 4.51 | -14.26% | $67.48M | vs COYA |
| MNOVMedicinova Inc | 1.31 | +3.15% | $67.11M | vs COYA |
| PLYXPolaryx Therapeutics Inc. | 1.33 | -11.92% | $66.30M | vs COYA |
| PMVPPMV Pharmaceuticals Inc. | 0.876 | -33.13% | $66.17M | vs COYA |
| GOSSGossamer Bio Inc. | 10.72 | -4.54% | $65.57M | vs COYA |
| FBIOFortress Biotech Inc. | 1.90 | +7.34% | $64.11M | vs COYA |
Indexes, lists and sector
Coya Therapeutics stock FAQ
What is Coya Therapeutics's stock price today?
COYA last traded at $2.95 as of Nov 20, 4:00 PM EST, down 1.01% on the day. Prices are delayed at least 15 minutes.
Who is Coya Therapeutics's CEO?
Dr. Arun Swaminathan Ph.D. is the chief executive officer of Coya Therapeutics Inc., which has about 8 employees.
What is the COYA 52-week high?
The 52-week high for COYA is $6.62 and the 52-week low is $2.72. The stock is currently 55.4% below its high.